MedTrace Logo

A Clinical Trial to Evaluate the Safety and Efficacy of IBS in Patients With Coronary Artery Disease

NCT05205499 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1059

Last updated 2025-12-10

No results posted yet for this study

Summary

A prospective, multi-center, single-arm trial to assess the safety and efficacy of the Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System (IBS) in treating patients with coronary artery disease.

Conditions

Interventions

DEVICE

Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System

Subjects in this arm will be treated with IBS

Sponsors & Collaborators

  • Biotyx Medical (Shenzhen) Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-10
Primary Completion
2024-07-01
Completion
2028-08-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05205499 on ClinicalTrials.gov